{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-001964","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2023-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.545274+00:00","generated_at":"2026-06-19T00:53:18.274121+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Passage Bio reports PBGM01 interim data: MRI stabilization, biomarker decreases in GM1 gangliosidosis trial","bullets":["All six treated patients showed stabilization of MRI severity scores over 6-12 months follow-up.","High-dose PBGM01 resulted in 3.6-5.2x increase in CSF β-gal activity, sustained up to 12 months.","No treatment-related serious adverse events, DRG toxicity, or complications from ICM delivery.","Urine Dp5 levels decreased in high-dose patients, indicating peripheral β-gal activity.","Milder developmental delay at baseline associated with improved treatment response."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-001964","json":"https://secwatch.observer/filing/0001558370-23-001964.json","markdown":"https://secwatch.observer/filing/0001558370-23-001964.md","text":"https://secwatch.observer/filing/0001558370-23-001964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023001964/0001558370-23-001964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023001964/pasg-20230224x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T00:53:18.274121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}